What is Helex?
Helex is a New York-based biotechnology company established in 2021, dedicated to developing advanced genomic medicines for kidney diseases. The company leverages its proprietary lipid nanoparticle technology for precise delivery to renal cells, combined with its Epic-Cure technology platform. This platform utilizes deep-learning models to design and validate CRISPR-based gene editing tools, enabling the prediction of edit outcomes to ensure therapeutic safety and efficacy. Helex's primary therapeutic target is Autosomal Dominant Polycystic Kidney Disease, reflecting its commitment to addressing unmet needs in chronic kidney disease treatment.
How much funding has Helex raised?
Helex has raised a total of $3.5M across 1 funding round:
Seed
$3.5M
Seed (2025): $3.5M with participation from Pi Ventures
Key Investors in Helex
Pi Ventures
Pi Ventures is a venture capital firm based in Bangalore, India, founded in 2016. It specializes in investments within the artificial intelligence, machine learning, and IoT sectors.
What's next for Helex?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Helex. This capital infusion is expected to accelerate the development and clinical progression of its gene editing therapeutics for renal indications. The company's focus on data-driven design and targeted delivery positions it to potentially revolutionize treatment paradigms for chronic kidney diseases, attracting further investment and strategic partnerships as it moves towards commercialization.
See full Helex company page
